John Woock Sells 30,215 Shares of Axonics, Inc. (NASDAQ:AXNX) Stock

Axonics, Inc. (NASDAQ:AXNX – Get Rating) EVP John Woock sold 30,215 shares of the stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $67.34, for a total value of $2,034,678.10. Following the completion of the transaction, the executive vice president now directly owns 45,976 shares in the company, valued at approximately $3,096,023.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Axonics Trading Down 0.3 %

NASDAQ:AXNX opened at $61.84 on Friday. Axonics, Inc. has a 12-month low of $38.41 and a 12-month high of $79.92. The stock has a 50-day moving average price of $63.46 and a 200 day moving average price of $67.10. The stock has a market capitalization of $3.06 billion, a P/E ratio of -37.48 and a beta of 0.43.

Axonics (NASDAQ:AXNX – Get Rating) last released its earnings results on Monday, October 31st. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.13. Axonics had a negative return on equity of 15.63% and a negative net margin of 31.35%. The firm had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $62.98 million. During the same quarter last year, the business posted ($0.38) earnings per share. The firm’s revenue was up 50.0% on a year-over-year basis. On average, research analysts predict that Axonics, Inc. will post -1.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AXNX has been the topic of a number of recent research reports. Piper Sandler increased their target price on Axonics from $82.00 to $84.00 and gave the company an “overweight” rating in a report on Wednesday, October 5th. Needham & Company LLC downgraded Axonics from a “buy” rating to a “hold” rating in a report on Monday, October 10th. Jefferies Financial Group started coverage on Axonics in a report on Wednesday, October 12th. They issued a “hold” rating and a $75.00 target price on the stock. Truist Financial decreased their price objective on Axonics from $90.00 to $82.00 and set a “buy” rating on the stock in a research note on Tuesday, December 20th. Finally, Morgan Stanley decreased their price objective on Axonics from $92.00 to $76.00 and set an “overweight” rating on the stock in a research note on Friday, January 6th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $78.11.

Institutional Trading of Axonics

Several institutional investors have recently made changes to their positions in AXNX. JPMorgan Chase & Co. grew its holdings in Axonics by 6.3% during the 1st quarter. JPMorgan Chase & Co. now owns 98,932 shares of the company’s stock valued at $6,192,000 after buying an additional 5,867 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in Axonics by 6.7% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 5,207 shares of the company’s stock valued at $326,000 after buying an additional 326 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Axonics by 1.0% during the 1st quarter. Bank of New York Mellon Corp now owns 209,484 shares of the company’s stock valued at $13,114,000 after buying an additional 2,038 shares in the last quarter. US Bancorp DE grew its holdings in Axonics by 15.5% during the 1st quarter. US Bancorp DE now owns 2,508 shares of the company’s stock valued at $157,000 after buying an additional 337 shares in the last quarter. Finally, Group One Trading L.P. grew its holdings in Axonics by 1,159.5% during the 1st quarter. Group One Trading L.P. now owns 5,038 shares of the company’s stock valued at $315,000 after buying an additional 4,638 shares in the last quarter. Hedge funds and other institutional investors own 97.49% of the company’s stock.

Axonics Company Profile

(Get Rating)

Axonics, Inc is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women.